首页> 外文期刊>American Journal of Hematology >Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT EBMT group
【24h】

Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT EBMT group

机译:患有FANCONI贫血患者的结果,培养骨髓细胞癌和急性白血病,他们接受同种异体造血干细胞移植:代表EBMT EBMT集团的回顾性分析

获取原文
获取原文并翻译 | 示例
       

摘要

Abstract Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is curative for bone marrow failure in patients with Fanconi anemia (FA), but the presence of a malignant transformation is associated with a poor prognosis and the management of these patients is still challenging. We analyzed outcome of 74 FA patients with a diagnosis of myelodysplastic syndrome (n = 35), acute leukemia (n = 35) or with cytogenetic abnormalities (n = 4), who underwent allo‐HSCT from 1999 to 2016 in EBMT network. Type of diagnosis, pre‐HSCT cytoreductive therapies and related toxicities, disease status pre‐HSCT, donor type, and conditioning regimen were considered as main variables potentially influencing outcome. The 5‐year OS and EFS were 42% (30‐53%) and 39% (27‐51%), respectively. Patients transplanted in CR showed better OS compared with those transplanted in presence of an active malignant disease (OS:71%[48‐95] vs 37% [24‐50], P =?.04), while none of the other variables considered had an impact. Twenty‐two patients received pre‐HSCT cytoreduction and 9/22 showed a grade 3‐4 toxicity, without any lethal event or negative influence on survival after HSCT(OS:toxicity pre‐HSCT 48% [20‐75%] vs no‐toxicity 51% [25‐78%], P =?.98). The cumulative incidence of day‐100 grade II‐IV a‐GvHD and of 5‐year c‐GvHD were 38% (26‐50%) and 40% (28‐52%). Non‐relapse‐related mortality and incidence of relapse at 5‐years were 40% (29‐52%) and 21% (11‐30%) respectively, without any significant impact of the tested variables. Causes of death were transplant‐related events in most patients (34 out of the 42 deaths, 81%). This analysis confirms the poor outcome of transformed FA patients and identifies the importance of achieving CR pre‐HSCT, suggesting that, in a newly diagnosed transformed FA patient, a cytoreductive approach pre‐HSCT should be considered if a donor have been secured.
机译:摘要同种异体造血干细胞移植(Allo-HSCT)是患有FANCONI贫血(FA)患者骨髓衰竭的疗效,但恶性转化的存在与差不多有关的预后和这些患者的管理仍然具有挑战性。我们分析了74例FA患者的结果,诊断骨髓增生综合征(n = 35),急性白血病(n = 35)或细胞遗传学异常(n = 4),他在1999年至2016年在EBMT网络中接受了Allo-HSCT。诊断类型,术前细胞染色疗法和相关毒性,疾病状态前HSCT,供体类型和调理方案被认为是潜在的影响结果的主要变量。 5年的OS和EFS分别为42%(30-53%)和39%(27-51%)。在CR中移植的患者与在活性恶性疾病存在下移植的患者(OS:71%[48-95] Vs 37%[24-50],P = 04),而没有其他变量考虑过造成影响。 22名患者接受了HSCT患者患者,9/22显示了3-4级毒性,而没有任何致命事件或HSCT后存活的负面影响(OS:毒性预先HSCT 48%[20-75%] VS-毒性51%[25-78%],p = 98)。 Day-100级-IV A-GVHD和5年C-GVHD的累积发生率为38%(26-50%)和40%(28-52%)。无复发相关的死亡率和5年复发的发病率分别为40%(29-52%)和21%(11-30%),无需任何明显的变量影响。死亡原因在大多数患者中有关移植相关事件(42例死亡中的34例,81%)。该分析证实转化的FA患者的结果差,并确定了实现CR预约HSCT的重要性,这表明,在新诊断的转化法患者中,如果捐赠者已被担保,则应考虑缩放的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号